esophageal cancer
Conditions
Interventions
Patients are stratified by the number of metastatic lymph node and the institute at the registration. Group A : FAP CDDP70mg/m2(day1) ADM35mg/m2(day1), and 5-FU700mg/m2(day1-7) following 3 week res
Sponsors
OGSG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Thoratic esophageal cancer proven squamous cell carcinoma histologically 2.cT1-4a without any distant metastasis (eligible if only with supraclavicular lymph node tumor) 3.patients older than 20 y.o. 4.PS(ECOG) : 0,1 or 2 5.without any prior chemotherapy for esophageal cancer 6.with good organ functions : WBC : 3,000/mm3 <= and >= 12,000/mm3 Neutrophile : 1,500/mm3 <= Hemoglobin : 9.0g/dl <= Platelet : 100,000/mm3 <= T.bil. : under one and a half time of normal limit AST,ALT : under two times of normal limit Creatinine clearance : >=60 (Eligeble in direct method or Cockcroft-Gault method) SpO2 >= 95% in room air 7.with written Informed Consent
Exclusion criteria
Exclusion criteria: 1.Unresectable due to severe organ dysfunction (brain, heart, lung, liver, and/or kidney) 2.With active double cancers 3.With the history of severe drug allergy 4.Pregnant and/or nursing women, or women who expect to be pregnant 5.Patients whom doctor in chief decides not to register to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of R0 resection Complications of surgery Overall survival Adverse events Response rates | — |
Countries
Japan
Contacts
Public ContactHiroshi Furukawa
Kinki University School of Medicine Department of surgery
Outcome results
None listed